Literature DB >> 7970903

Plasma interleukin-1 alpha and beta, tumor necrosis factor-alpha, and lipopolysaccharide concentrations during pulmonary exacerbations of cystic fibrosis.

R W Wilmott1, M Frenzke, V Kociela, L Peng.   

Abstract

Earlier studies have reported the presence of interleukin-1 (IL-1) and tumor necrosis factor (TNF) in the plasma of patients with cystic fibrosis (CF), but the results have been inconsistent. To investigate the relationships among plasma IL-1 alpha, IL-1 beta, TNF, lipopolysaccharide (LPS), and clinical status, measurements were made before and after 14 days of intravenous antibiotic therapy in 13 patients with CF. In addition, whole blood cytokine production rates were measured in 18 hr cultures stimulated with 10 micrograms/mL LPS or sterile saline (control). On admission, patients with CF had significantly greater plasma levels of LPS and IL-1 alpha compared with 20 healthy adult controls. In response to antibiotic therapy, the patients had statistically significant increases in weight, oxygen saturation, chest radiograph score, and forced expiratory volume in 1 second. They had significant decreases in pulse rate, residual volume/total lung capacity ratio, white blood count, neutrophil count, LPS concentration, and resting energy expenditure per kg body weight. There were no significant changes in the plasma concentrations of IL-1 alpha, IL-1 beta, or TNF and no significant changes in the basal or stimulated whole blood production rates of IL-1 alpha, IL-1 beta, or TNF. The immunological variables did not correlate significantly with clinical measurements of severity or the presence of fever. It is likely that in CF local pulmonary effects of cytokines are of more pathophysiologic significance than systemic effects.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7970903     DOI: 10.1002/ppul.1950180107

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  8 in total

1.  Inflammatory markers of lung disease in adult patients with cystic fibrosis.

Authors:  Hara Levy; Leslie A Kalish; Ian Huntington; Nathaniel Weller; Craig Gerard; Edwin K Silverman; Juan C Celedón; Gerald B Pier; Scott T Weiss
Journal:  Pediatr Pulmonol       Date:  2007-03

Review 2.  Monitoring inflammation in CF. Cytokines.

Authors:  Scott D Sagel; Frank J Accurso
Journal:  Clin Rev Allergy Immunol       Date:  2002-08       Impact factor: 8.667

3.  Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project.

Authors:  G Steinkamp; B Wiedemann
Journal:  Thorax       Date:  2002-07       Impact factor: 9.139

Review 4.  Sputum biomarkers of inflammation in cystic fibrosis lung disease.

Authors:  Scott D Sagel; James F Chmiel; Michael W Konstan
Journal:  Proc Am Thorac Soc       Date:  2007-08-01

5.  Matrilysin expression and function in airway epithelium.

Authors:  S E Dunsmore; U K Saarialho-Kere; J D Roby; C L Wilson; L M Matrisian; H G Welgus; W C Parks
Journal:  J Clin Invest       Date:  1998-10-01       Impact factor: 14.808

6.  Endotoxin neutralization as a biomonitor for inflammatory bowel disease.

Authors:  Keith Champion; Laura Chiu; John Ferbas; Michael Pepe
Journal:  PLoS One       Date:  2013-06-24       Impact factor: 3.240

7.  Potential of anti-inflammatory treatment for cystic fibrosis lung disease.

Authors:  Jennifer L Taylor-Cousar; Kelsey A Von Kessel; Robert Young; David P Nichols
Journal:  J Inflamm Res       Date:  2010-08-10

8.  Corticosteroid use and increased CXCR2 levels on leukocytes are associated with lumacaftor/ivacaftor discontinuation in cystic fibrosis patients homozygous for the F508del CFTR mutation.

Authors:  Kerstin Pohl; David P Nichols; Jennifer L Taylor-Cousar; Milene T Saavedra; Matthew J Strand; Jerry A Nick; Preston E Bratcher
Journal:  PLoS One       Date:  2018-12-12       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.